BioCryst Pharmaceuticals
BCRX
$4.16
Share price
0.00%
Change (1 day)
-45.34%
Change (1 year)
Categories
BioCryst Pharmaceuticals (BCRX) - P/B ratio
P/B ratio as of April 2024 : -1.88
According to BioCryst Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of -1.88.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
BioCryst Pharmaceuticals - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -2.69 | -62.93% |
| 2022-12-31 | -7.26 | -68.81% |
| 2021-12-31 | -23.3 | -65.89% |
| 2020-12-31 | -68.3 | -591.41% |
| 2019-12-31 | 13.9 | -22.97% |
| 2018-12-31 | 18.0 | 212.76% |
| 2017-12-31 | 5.77 | -98.05% |
| 2016-12-31 | 296 | 1765.24% |
| 2015-12-31 | 15.9 | 37.12% |
| 2014-12-31 | 11.6 | -102.9% |
| 2013-12-31 | -399 | 150.56% |
| 2012-12-31 | -159 | -2210.4% |
| 2011-12-31 | 7.54 | 112.56% |
| 2010-12-31 | 3.55 | 7.92% |
| 2009-12-31 | 3.29 | 191.24% |
| 2008-12-31 | 1.13 | -68.77% |
| 2007-12-31 | 3.62 | -77.38% |
| 2006-12-31 | 16.0 | 93.53% |
| 2005-12-31 | 8.26 | 92.63% |
| 2004-12-31 | 4.29 | -0.37% |
| 2003-12-31 | 4.30 | 918.74% |
| 2002-12-31 | 0.4224 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 3.59 | -290.48% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.16 | -373.90% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 14.2 | -852.22% | 🇺🇸 USA |
 Repligen
RGEN | 4.72 | -350.65% | 🇺🇸 USA |
 Novavax NVAX | -0.7984 | -57.59% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 5.56 | -395.17% | 🇺🇸 USA |
 NanoViricides NNVC | 1.04 | -155.28% | 🇺🇸 USA |
 Cel-Sci
CVM | 6.14 | -426.38% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.1549 | -108.23% | 🇺🇸 USA |